Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T29143
(Former ID: TTDC00177)
|
|||||
| Target Name |
Interleukin-13 (IL13)
|
|||||
| Synonyms |
NC30; IL-13
Click to Show/Hide
|
|||||
| Gene Name |
IL13
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Atopic eczema [ICD-11: EA80] | |||||
| Function |
Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses. Positively regulates IL31RA expression in macrophages. Cytokine.
Click to Show/Hide
|
|||||
| BioChemical Class |
Cytokine: interleukin
|
|||||
| UniProt ID | ||||||
| Sequence |
MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAP
LCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRD TKIEVAQFVKDLLLHLKKLFREGRFN Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
| HIT2.0 ID | T50GQE | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Tralokinumab | Drug Info | Approved | Atopic dermatitis | [2] | |
| Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
| 1 | Lebrikizumab | Drug Info | Phase 3 | Severe asthma | [5], [6] | |
| 2 | Anrukinzumab | Drug Info | Phase 2 | Ulcerative colitis | [9], [10], [11] | |
| 3 | PEGylated pitrakinra | Drug Info | Phase 2 | Asthma | [12], [13] | |
| 4 | QAX-576 | Drug Info | Phase 2 | Allergic rhinitis | [14] | |
| 5 | SAR-156597 | Drug Info | Phase 2 | Pulmonary fibrosis | [15] | |
| 6 | CNTO-5825 | Drug Info | Phase 1 | Allergic asthma | [19] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Tralokinumab | Drug Info | [21] | |||
| Modulator | [+] 5 Modulator drugs | + | ||||
| 1 | Lebrikizumab | Drug Info | [1] | |||
| 2 | Anrukinzumab | Drug Info | [22] | |||
| 3 | PEGylated pitrakinra | Drug Info | [1] | |||
| 4 | QAX-576 | Drug Info | [23] | |||
| 5 | SAR-156597 | Drug Info | [24] | |||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Pathway Affiliation
Biological Network Descriptors
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
| KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
|---|---|---|---|
| Cytokine-cytokine receptor interaction | hsa04060 | Affiliated Target |
|
| Class: Environmental Information Processing => Signaling molecules and interaction | Pathway Hierarchy | ||
| JAK-STAT signaling pathway | hsa04630 | Affiliated Target |
|
| Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
| IL-17 signaling pathway | hsa04657 | Affiliated Target |
|
| Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
| Th1 and Th2 cell differentiation | hsa04658 | Affiliated Target |
|
| Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
| Fc epsilon RI signaling pathway | hsa04664 | Affiliated Target |
|
| Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
| Degree | 16 | Degree centrality | 1.72E-03 | Betweenness centrality | 2.45E-04 |
|---|---|---|---|---|---|
| Closeness centrality | 2.25E-01 | Radiality | 1.40E+01 | Clustering coefficient | 2.83E-01 |
| Neighborhood connectivity | 2.88E+01 | Topological coefficient | 1.14E-01 | Eccentricity | 11 |
| Download | Click to Download the Full PPI Network of This Target | ||||
| Target Regulators | Top | |||||
|---|---|---|---|---|---|---|
| Target-regulating microRNAs | ||||||
| Target-regulating Transcription Factors | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 6 KEGG Pathways | + | ||||
| 1 | Cytokine-cytokine receptor interaction | |||||
| 2 | Jak-STAT signaling pathway | |||||
| 3 | Fc epsilon RI signaling pathway | |||||
| 4 | Measles | |||||
| 5 | Asthma | |||||
| 6 | Inflammatory bowel disease (IBD) | |||||
| NetPath Pathway | [+] 5 NetPath Pathways | + | ||||
| 1 | IL9 Signaling Pathway | |||||
| 2 | TCR Signaling Pathway | |||||
| 3 | IL2 Signaling Pathway | |||||
| 4 | Leptin Signaling Pathway | |||||
| 5 | TSLP Signaling Pathway | |||||
| Panther Pathway | [+] 1 Panther Pathways | + | ||||
| 1 | Interleukin signaling pathway | |||||
| Pathwhiz Pathway | [+] 1 Pathwhiz Pathways | + | ||||
| 1 | Fc Epsilon Receptor I Signaling in Mast Cells | |||||
| PID Pathway | [+] 2 PID Pathways | + | ||||
| 1 | Glucocorticoid receptor regulatory network | |||||
| 2 | IL12 signaling mediated by STAT4 | |||||
| WikiPathways | [+] 3 WikiPathways | + | ||||
| 1 | SIDS Susceptibility Pathways | |||||
| 2 | Cytokines and Inflammatory Response | |||||
| 3 | Allograft Rejection | |||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. | |||||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761180. | |||||
| REF 3 | ClinicalTrials.gov (NCT05763121) A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma. U.S.National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT05214768) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis. U.S.National Institutes of Health. | |||||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7684). | |||||
| REF 6 | ClinicalTrials.gov (NCT01875003) A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication. U.S. National Institutes of Health. | |||||
| REF 7 | ClinicalTrials.gov (NCT01266135) Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | |||||
| REF 8 | ClinicalTrials.gov (NCT02345070) Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (ESTAIR). U.S. National Institutes of Health. | |||||
| REF 9 | ClinicalTrials.gov (NCT00425061) Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma. U.S. National Institutes of Health. | |||||
| REF 10 | ClinicalTrials.gov (NCT00410280) Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma | |||||
| REF 11 | ClinicalTrials.gov (NCT01284062) Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients | |||||
| REF 12 | ClinicalTrials.gov (NCT00801853) A Study of the Treatment-Sparing Effects of AEROVANT AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL | |||||
| REF 13 | ClinicalTrials.gov (NCT00676884) A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema | |||||
| REF 14 | ClinicalTrials.gov (NCT01266135) Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | |||||
| REF 15 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034106) | |||||
| REF 16 | ClinicalTrials.gov (NCT05496738) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07264660 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health. | |||||
| REF 17 | ClinicalTrials.gov (NCT05411588) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07275315 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health. | |||||
| REF 18 | ClinicalTrials.gov (NCT05366764) A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma. U.S.National Institutes of Health. | |||||
| REF 19 | ClinicalTrials.gov (NCT01081691) A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers. U.S. National Institutes of Health. | |||||
| REF 20 | ClinicalTrials.gov (NCT02748642) A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma. U.S. National Institutes of Health. | |||||
| REF 21 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 22 | Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900. | |||||
| REF 23 | Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7. | |||||
| REF 24 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. | |||||
| REF 25 | Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.